Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Tadaaki Nishikawa"'
Autor:
Risako Ozawa, Tadaaki Nishikawa, Kasumi Yamamoto, Tatsunori Shimoi, Mitsuya Ishikawa, Tomoyasu Kato, Kan Yonemori
Publikováno v:
Gynecologic Oncology Reports, Vol 55, Iss , Pp 101479- (2024)
Lenvatinib plus pembrolizumab (LP) therapy is currently used in patients with advanced or recurrent endometrial cancer. However, patients with uterine carcinosarcoma (UCS) were not included in the KEYNOTE-775, and the efficacy of LP therapy for patie
Externí odkaz:
https://doaj.org/article/7000a99a76ee49c3a0ab69bfa248053a
Autor:
Sho Watanabe, Tatsunori Shimoi, Tadaaki Nishikawa, Asuka Kawachi, Hitomi Sumiyoshi Okuma, Momoko Tokura, Shu Yazaki, Chiharu Mizoguchi, Motoko Arakaki, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, Yuki Kojima, Kazuki Sudo, Emi Noguchi, Akihiko Yoshida, Akira Kawai, Yasuhiro Fujiwara, Kan Yonemori
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Prognostic value of hematologic indices and their association with the tumor microenvironment (TME) remain unclear in advanced soft tissue sarcoma (STS). We aimed to evaluate their prognostic value and correlation with the TME status in adva
Externí odkaz:
https://doaj.org/article/7169a5aae4cb428bbaf374a0faa34c96
Autor:
Yuki Kojima, Hiroshi Yoshida, Toshihiro Okuya, Hitomi S Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Tatsunori Shimoi, Kenji Tamura, Yasuhito Tanase, Masaya Uno, Mitsuya Ishikawa, Motoko Arakaki, Hitoshi Ichikawa, Shigehiro Yagishita, Akinobu Hamada, Yasuhiro Fujiwara, Kan Yonemori, Tomoyasu Kato
Publikováno v:
Gynecologic Oncology Reports, Vol 50, Iss , Pp 101302- (2023)
Background: Most cervical adenocarcinomas are associated with human papillomavirus (HPV). Gastric-type cervical adenocarcinoma (GAS), an HPV-independent adenocarcinoma, shows an aggressive clinical feature, resulting in a poor prognosis. Resistance t
Externí odkaz:
https://doaj.org/article/6ea628c1121a4c6caf801d05485e7145
Autor:
Yuki Kojima, Kazuki Sudo, Hiroshi Yoshida, Shu Yazaki, Momoko Tokura, Chiharu Mizoguchi, Hitomi S. Okuma, Shosuke Kita, Kasumi Yamamoto, Tadaaki Nishikawa, Emi Noguchi, Tatsunori Shimoi, Yasuhito Tanase, Masaya Uno, Mitsuya Ishikawa, Tomoyasu Kato, Kumiko Koyama, Maki Kobayashi, Tomoya Kakegawa, Yasuhiro Fujiwara, Kan Yonemori
Publikováno v:
Cancer Cell International, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Human epidermal growth factor receptor-3 (HER3) is a member of the epidermal growth factor receptor family of receptor tyrosine kinases, and its overexpression is associated with inferior prognosis in several cancers. However, it
Externí odkaz:
https://doaj.org/article/906d68d622e2442285a457d155246fd0
Autor:
Shigemasa Takamizawa, Shu Yazaki, Yuki Kojima, Hiroshi Yoshida, Rui Kitadai, Tadaaki Nishikawa, Tatsunori Shimoi, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Maki Tanioka, Emi Noguchi, Masaya Uno, Mitsuya Ishikawa, Tomoyasu Kato, Yasuhiro Fujiwara, Kan Yonemori
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Mesothelin (MSLN) is a cell-surface glycoprotein found in various solid tumours. Cancer therapies targeting MSLN have been developed in recent years; however, the available information on MSLN expression in cervical cancer is limi
Externí odkaz:
https://doaj.org/article/0d1ff421865b4a71af51806eb508282d
Autor:
Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Rui Kitadai, Asuka Kawachi, Shu Yazaki, Momoko Tokura, Motoko Arakaki, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, Aiko Maejima, Yuki Kojima, Tadaaki Nishikawa, Kazuki Sudo, Tatsunori Shimoi, Emi Noguchi, Yasuhiro Fujiwara, Hirokazu Sugino, Sho Shiino, Akihiko Suto, Masayuki Yoshida, Kan Yonemori
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionTriple-negative breast cancer (TNBC) is negative for hormone receptors and human epidermal growth factor receptor 2 (HER2). In stage I TNBC, adjuvant therapy or follow-up are performed according to risk factors, but clinical trial data is
Externí odkaz:
https://doaj.org/article/d1c7862b911d4555b6a5240fa9cffc46
Autor:
Shigemasa Takamizawa, Tatsunori Shimoi, Masayuki Yoshida, Momoko Tokura, Shu Yazaki, Chiharu Mizoguchi, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, Yuki Kojima, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Emi Noguchi, Kazuki Sudo, Kan Yonemori
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Routine measurement of tumor markers is not recommended in daily clinical practice for patients with cancer of unknown primary (CUP). We evaluated the diagnostic value of tumor markers in identifying favorable or unfavorable subse
Externí odkaz:
https://doaj.org/article/d23e0071b7ef404aa69907d7bc7e6912
Autor:
Sho Sato, Hirokazu Matsushita, Daisuke Shintani, Yukari Kobayashi, Nao Fujieda, Akira Yabuno, Tadaaki Nishikawa, Keiichi Fujiwara, Kazuhiro Kakimi, Kosei Hasegawa
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Regulatory T cells (Tregs) play an important role in the antitumor immune response in epithelial ovarian cancer (EOC). To understand the immune-inhibitory networks of EOC, we addressed the association between Tregs and immune chec
Externí odkaz:
https://doaj.org/article/f10f251127df4fddad29a4a9e9fb4658
Autor:
Shigemasa Takamizawa, Tatsunori Shimoi, Natsuko Satomi-Tsushita, Shu Yazaki, Toshihiro Okuya, Yuki Kojima, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Kan Yonemori
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors
Externí odkaz:
https://doaj.org/article/1a3d1d1d78eb446a83f9afbf76e57338
Autor:
Yuki Kojima, Emi Noguchi, Tomomi Yoshino, Shigehiro Yagishita, Shu Yazaki, Hitomi S. Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Ayaka Kazama, Hiroshi Terasaki, Sachiro Asano, Yasuhiro Fujiwara, Akinobu Hamada, Kenji Tamura, Kan Yonemori
Publikováno v:
Diagnostics, Vol 13, Iss 12, p 2040 (2023)
Although circulating tumour DNA (ctDNA)-based next-generation sequencing (NGS) is a less invasive method for assessing ESR1 mutations that are essential mechanisms of endocrine therapy resistance in patients with oestrogen receptor-positive breast ca
Externí odkaz:
https://doaj.org/article/5c672b95ed7649a29f346277c875dfae